Selank comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-01. Numbers and descriptions here follow the published literature rather than marketing material.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
If compelling archaeological reasons for supposing that the ages come from exactly contemporary samples do not exist, then results must be regarded as suspect. If there exists no prior reason to believe that two samples are truly of the same age, and even if their ages are statistically indistinguishable, they are as likely to be as far apart in true age as the measured difference between them as they are to be of the same age. Charcoal was seen historically as an ideal medium for carbon dating. When long-lived tree species, such as oak and juniper, are used, however, there is a particular danger of encountering the "old wood" problem. For example, the date being measured may be from heartwood, which is already many centuries old by the time the tree was felled. Another difficulty is that of a possible time-lag between felling and final deposition. The timber may have had an extensive history of use and re-use. A method of ameliorating this problem is to date young growth, if available, for example hazel twigs. Dating of artefacts using accelerator mass spectrometry is the gold standard dating method of today; charcoal-sourced dates are seen as unreliable. In establishing the chronology of a site, a representative spread of dates is required before interpretation can be attempted.
== Potential drug interactions == CoQ10 taken as a pharmacological substance has potential to inhibit the effects of theophylline as well as the anticoagulant warfarin; CoQ10 may interfere with warfarin's actions by interacting with cytochrome p450 enzymes thereby reducing the INR, a measure of blood clotting. The structure of CoQ10 is similar to that of vitamin K, which competes with and counteracts warfarin's anticoagulation effects. CoQ10 is not recommended in people taking warfarin due to the increased risk of clotting.
=== Caedi McFarlane === Caedi McFarlane (Eliot Salt) is Henry Muck's personal assistant at Lumi, whose presence often calms him during his erratic outbursts. Caedi later files an anonymous complaint against Henry for repeated sexual harassment, which is mentioned in the government inquest against Lumi following its collapse.
=== Interstitial cytotrophoblast === The primary function of an interstitial cytotrophoblast is to anchor the growing fetus to the maternal uterine tissue. These cells may invade the whole endometrium and the proximal third of the myometrium. Once these cells penetrate through the first few layers of cells of the decidua, they lose their ability to proliferate and become invasive. This departure from the cell cycle seems to be due to factors such as TGF-β and decorin. Although these invasive interstitial cytotrophoblasts can no longer divide, they retain their ability to form syncytia. Multinucleated giant cells (small syncytia) are found in the placental bed and myometrium as a result of the fusion of interstitial cytotrophoblasts. Interstitial cytotrophoblasts may also transform into endovascular cytotrophoblasts.
=== Michael "Mike" Franks === Special Agent-in-Charge Michael Aaron Franks, NIS/NCIS (Ret.) (Muse Watson) is introduced in episode flashbacks in the episode "Hiatus" (Part 1). He is Gibbs' former boss, mentor and partner, still referring to Gibbs as "Probie", just as DiNozzo does with McGee. In "Hiatus" (Part 2), it is stated that he retired to Mexico in 1996, roughly five years after Gibbs joined NIS/NCIS, after becoming outraged with the government's failure to prevent the Khobar Towers bombing. He comes across as callous and uncaring, keeping his feelings and his personal life tightly under wraps, even hiding the fact that he had a grown son until he needed Gibbs' help to protect his granddaughter and the girl's mother, Leyla, after his son is killed. Gibbs has picked up many of his traits, including the trademark head slap he gives to DiNozzo, and his ability to find a way around red tape. NCIS Director Jenny Shepard brings him back in hopes of helping Gibbs regain his memory after suffering a concussion in part 2 of "Hiatus". Franks is the only survivor of the gun battle that ends Director Shepard's life, and is the last living person to know about her incurable illness during her lifetime, as Gibbs only has suspicions at the time of "Judgment Day" (Part 1). In his visit to Gibbs' bedside in season three, it is revealed in flashbacks that he warned members of the intelligence community about the threat that Osama bin Laden posed to American servicemen abroad some time before the Khobar Towers bombing.
Sources: en.wikipedia.org
During the initial 4 to 6 hours following the power change, the magnitude and the rate of change of concentration is dependent upon the initial power level and on the amount of change in power level; the 135Xe concentration change is greater for a larger change in power level. When reactor power is decreased, the process is reversed. Iodine-135 is a fission product of uranium with a yield of about 6% (counting also the 135I produced almost immediately from decay of fission-produced tellurium-135). This 135I decays with a 6.58 hour half-life to 135Xe. Thus, in an operating nuclear reactor, 135Xe is being continuously produced. 135Xe has a very large neutron absorption cross-section, so in the high-neutron-flux environment of a nuclear reactor core, the 135Xe soon absorbs a neutron and becomes effectively stable 136Xe. (The half-life of 136Xe is >1021 years, and it is not treated as a radioisotope.) Thus, in about 50 hours, the 135Xe concentration reaches equilibrium where its creation by 135I decay is balanced with its destruction by neutron absorption. When reactor power is decreased or shut down by inserting neutron-absorbing control rods, the reactor neutron flux is reduced and the equilibrium shifts initially towards higher 135Xe concentration. The 135Xe concentration peaks about 11 hours after reactor power is decreased. Since 135Xe has a 9.14 hour half-life, the 135Xe concentration gradually decays back to low levels over 72 hours.
== Medical uses == In the United States, dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In the European Union, it is indicated in adults aged 18 years and older with type 2 diabetes:
Fredric John Baur Jr. (July 14, 1918 – May 4, 2008) was an American organic chemist and food storage scientist notable for designing the Pringles packaging. Baur filed for a patent for the tubular Pringles container and for the method of packaging the curved, stacked potato chip in the container in 1966, and it was granted in 1971. His other accomplishments included development of frying oils and freeze-dried ice cream. Baur was a graduate of the University of Toledo in Toledo, Ohio, and received both his master's and PhD degrees in organic chemistry at Ohio State University. He also served in the U.S. Navy as an aviation physiologist. He was a resident of Cincinnati, Ohio. Baur died on May 4, 2008 at the age of 89 due to Alzheimer's disease. Some of Baur's ashes were buried in a Pringles can at his request. Baur's children said they honored his request to bury him in one of the cans by placing part of his cremated remains in an Original flavor Pringles container in his grave in suburban Springfield Township. The rest of his remains were placed in an urn buried along with the can, with some placed in another urn and given to one of Baur's grandchildren.
==== Hypoglycemic glucagon impairment ==== Glucagon secretion is normally increased upon falling glucose levels, but normal glucagon response to hypoglycemia is blunted in type 1 diabetics. Beta cell glucose sensing and subsequent suppression of administered insulin secretion is absent, leading to islet hyperinsulinemia which inhibits glucagon release. Autonomic inputs to alpha cells are far more important for glucagon stimulation in the moderate to severe ranges of hypoglycemia, yet the autonomic response is blunted in several ways. Recurrent hypoglycemia leads to metabolic adjustments in the glucose-sensing areas of the brain, shifting the threshold for counterregulatory activation of the sympathetic nervous system to lower glucose concentration. This is known as hypoglycemic unawareness. Subsequent hypoglycemia is met with impairment in the sending of counter-regulatory signals to the islets and adrenal cortex. This accounts for the lack of glucagon stimulation and epinephrine release that would normally stimulate and enhance glucose release and production from the liver, rescuing the diabetic from severe hypoglycemia, coma, and death. Numerous hypotheses have been produced in the search for a cellular mechanism of hypoglycemic unawareness. A consensus has yet to be reached. The major hypotheses are summarized in the following table:
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.